Recent Updates
Recently added Catalysts
REPL Negative Sentiment Score: 20/100

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Key Takeaway: Replimune Group, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a disappointing FDA response. The FDA issued a Complete Response Letter regarding Replimune's Biologics License Application for RP1, citing inadequate evidence of effectiveness from the IGNYTE trial. As a result of the negative announcement, the company's stock plummeted more than 77%, raising concerns among investors. The law firm is reaching out to affected investors to explore legal options for recovering losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Replimune Group received a Complete Response Letter from the FDA, indicating significant issues with its BLA for RP1.
  • The FDA found the IGNYTE trial insufficiently controlled, questioning the evidence of effectiveness.
  • Following the news, Replimune's stock saw a sharp decline of over 77%, falling to $2.80 per share.
  • Investors are being targeted by a law firm for possible securities fraud, indicating potential legal troubles for the company.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Replimune investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On July 22, 2025, prior to market open, Replimune Group, Inc. issued a press release titled “Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma.” The company disclosed that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
According to the press release, the FDA declined to approve the application in its current form, stating that the IGNYTE trial was not considered an adequate and well-controlled clinical investigation capable of providing substantial evidence of effectiveness.
Following the announcement, Replimune’s stock declined sharply, falling $9.52 per share (a drop of more than 77%), closing at $2.80 on July 22, 2025.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
Attorney Advertising

Tags

Frequently Asked Questions

What is the Portnoy Law Firm investigating?

The Portnoy Law Firm is looking into potential securities fraud related to Replimune.

How can Replimune investors contact the firm?

Investors can reach attorney Lesley F. Portnoy at 310-692-8883 or info@portnoylaw.com.

What triggered the investigation into Replimune?

The investigation follows a Complete Response Letter from the FDA regarding Replimune's application.

What was the stock decline after the FDA announcement?

Replimune's stock dropped over 77%, falling $9.52 per share to close at $2.80.

Is there a cost for the case evaluation?

No, the Portnoy Law Firm offers a complimentary evaluation for investors.

Last updated: Jul 25, 2025